B-PLL is a rare subtype that’s more aggressive than other blood cancers and has a low survival rate. However, ongoing research and clinical trials may offer new treatment options to improve outcomes.

About 30 percent of all non-Hodgkin lymphoma diagnoses in the United States are DLBCL. Although it is an aggressive cancer that can spread quickly, it is treatable. These can be symptoms of many ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During ...

Stage 4 diffuse large B-cell lymphoma (DLBCL) is a rapidly growing lymphoma affecting at least one other organ outside the lymphatic system. Cancer is the unusual growth and spread of cells within the ...

B-cell prolymphocytic leukemia (B-PLL) is a rare, aggressive type of leukemia that progresses rapidly. People with B-PLL typically have a less favorable outlook. However, new targeted treatments in ...

Please provide your email address to receive an email when new articles are posted on . Learning from 2 decades of off-label rituximab use in systemic lupus erythematosus may point the way toward ...

The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...

Please provide your email address to receive an email when new articles are posted on . A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the ...

Researchers from the School of Veterinary Medicine and Perelman School of Medicine have found that YY1 knockout pro-B cells can generate T lineage cells helping B cells produce antibodies. Development ...